Firebrick Pharma Receives Australian Patent for Nasodine Nasal Spray
Firebrick Pharma Limited said an Australian patent has been awarded for its Nasodine nasal spray, a product formulated to help prevent COVID-19 infection. The patent covers Nasodine’s use in lowering viral load and preventing infection, offering commercial protection through to 2040.
International Patent Rights and Commercialization
The protection for Nasodine is not limited to Australia; corresponding rights extend to the United States, Europe, South Africa and Mexico. Firebrick said the granted patent strengthens its ability to commercialize the product across multiple jurisdictions.
Company Focus and Market Expansion
Firebrick Pharma focuses on developing and commercializing novel povidone-iodine (PVP-I) formulations. The company has launched Nasodine and is growing its footprint in the United States, Singapore, Fiji and the South Pacific, with plans to enter the Philippines in 2026.
Market Indicators
Market indicators show an average trading volume of 93,735 for FRE and a technical sentiment signal of "Buy." For a more detailed look at the stock, consult Tip...